Quest Diagnostics Stock News

Smart Beta ETF report for FXH

Monthly update of the Dividend Champions List. 139 companies declared higher dividends in the past month, with an average increase of 10.54% over their previous payouts.

UBS downgraded Quest Diagnostics stock to "neutral" from "buy"

UBS has downgraded Quest Diagnostics (DGX) from buy to neutral on fears the company wont be able to meet its own earnings target in 2023.

UBS said Quest''s 2023 earnings guidance may be too aggressive given the company''s rising costs.

Sector ETF report for FXH

Quest Diagnostics Inc (NYSE:DGX) stock is flat this morning, last seen 0.1% higher to trade at $130.71, after UBS downgraded the medical lab operator's shares to "neutral" from "buy.

Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0

Analysts have provided the following ratings for Quest Diagnostics (NYSE: DGX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 3 0 0 2M Ago 0 0 2 0 0 3M Ago 0 1 1 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Quest Diagnostics. The company has an average price target of $151.62 with a high of $170.00 and a low of $129.00. Below is a summary of how these 8 analysts rated Quest Diagnostics over the … Full story available on Benzinga.com

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

Companies that provide at-home diagnostic testing kits weren't on many investors' radars before the Covid-19 pandemic. However, many people have wished at least once in their lives that they could ord

Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Fecal Occult Testing Market 2021-2025" report has been added to ResearchAndMarkets.com''s offering. The global fecal occult testing market is poised to grow by $113.49 million during 2021-2025, progressing at a CAGR of 4.41% during the forecast period. The market is driven by rising geriatric population and increasing prevalence of CRC. The study identifies the increasing number of government initiatives for CRC screening tests as one of the prime reasons driving the fecal occult testing market growth during the next few Full story available on Benzinga.com

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q4 2021 Results - Earnings Call Transcript

Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.

Quest Diagnostics (DGX) is trading ~3% lower in the pre-market despite earnings beat after announcing a change in its leadership team. The company has named James E